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Both animal and human studies have shown beneficial effects of administered nitric oxide (NO) on platelet function 1 and minimization of SIRS after exposure of blood to extracorporeal circuits. Equally importantly, ischaemia/reperfusion injury can be lessened in many organs, including the brain 2 and the heart, 3 with the administration of NO or nitric oxide donors prior to or concomitant with reperfusion. A randomized control trial by James et al. showed that the addition of 20 ppm of NO to the oxygenator gas flow during cardiopulmonary bypass (CPB) for children having cardiac surgery for congenital heart disease reduced the incidence of postoperative low cardiac output syndrome; 4 this study supported the findings of Checchia et al. who had previously shown reduced inflammatory response and decreased duration of mechanical ventilation in children with Tetralogy of Fallot undergoing repair on CPB. 5 Hence, we hypothesized that adding NO to the fresh gas flow of the oxygenator when ECMO was initiated and then continuing the NO would potentially limit ischaemia/ reperfusion injury as well as contact activation of platelets and white blood cells.
NO comes at a concentration of 800 ppm and, in order to have 20 ppm, a total fresh gas flow of at least 3 litres per minute is needed. This is easy to achieve on CPB, with the addition of CO 2 and a perfusionist present continuously. This can also be done on ECMO in adults or larger patients, but with small patients, small oxygenators and lower blood flow (500 mls/min or so) there is a possibility that 3 litres per min of gas flow can lead to a high pressure on the gas side of the membrane and, hence, a potential gas to blood leak and gas embolism. In order to avoid this potential problem, we have chosen to use 3 litres per min total gas flow (allows DSIR unit to control NO ppm) and add a combination low-flow and pressure release valve to our ECMO circuit, as shown in Figure 1 .
The hospital ethics committee approved the initial study (HREC BD031) which was designed to evaluate the utility and safety of NO and ECMO. We administered 20 ppm of NO into the oxygenator circuit with the other gases (air/oxygen) from ECMO initiation. We included all children cannulated for ECMO from April 2016 until December 2016. During the study period. all 30 children (31 runs) supported with ECMO received 20 ppm of NO administered through the oxygenator. One child received two ECMO runs. In 11 children (35%), a cardiac arrest was the cause for ECMO initiation, while 10 (32%) failed to respond to maximal medical therapy and 6 cardiac patients (19%) failed to wean off CPB. Median peak methaemoglobin level was 1.2% (0.4-2.6%); no child required cessation of NO or administration of methylene blue during the NO administration. Eight children (26%) required haemofiltration during the ECMO run, but only one died. Overall, 25 children survived to hospital discharge (83%); five children died (13%). Three children failed to wean off ECMO and were palliated. Of the two weaned off ECMO, one child died of multiorgan failure after further cardiac surgery while the other was discharged interstate to another hospital for weaning off mechanical ventilation; he subsequently died there. The child who had two ECMO runs survived. Diagnosis, blood product usage and hours of ECMO support are described in Table 1 .
We compared the data of the NO on ECMO population to the data of all children receiving ECMO over the prior 3 years (Table 1 ). There was no difference between these 101 children (120 runs) and those 30 children receiving ECMO without NO over the 3 years previous to April 2016; there was no statistical difference noted in age at ECMO initiation, weight, diagnosis, reason for ECMO, use of inhaled NO pre-ECMO, pH pre-ECMO, end-organ dysfunction pre-ECMO (cardiac arrest, sepsis, DIC, liver dysfunction), type of cannulation (central vs. peripheral) or average blood flow. Thirty-three of these 101 children died (5 of 30 with NO died).
In our experience, giving NO into the gas phase of the oxygenator in children receiving ECMO has proven to be safe and does not cause adverse effects. Although a small number of patients, there was no significant occurrence of methaemoglobinaemia or bleeding. Increasing evidence in animal and human studies point to the protective role of NO in controlling cellular death during ischaemia and reperfusion injury in the myocardium, brain, lung and liver and NO is also involved in mitigating the "blood/plastic" interaction through inhibition of platelet aggregation and leukocyte activation. This pilot study was not designed to evaluate clinical benefit, but the results appeared no worse and a possible improvement in survival (especially following cardiac arrest). Current animal research is continuing in Ann Arbor, Michigan, evaluating these blood/ circuit interactions and the role of NO as well as possible dose effects. Clearly more research is needed to document safety and evaluate efficacy and consideration towards a randomized control trial awaits this information.
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